Original Wu Yue Minenet
Highlights
Recently, the official website of the State Food and Drug Administration announced the latest announcement on the acceptance of the protection of traditional Chinese medicine varieties, and Jiangsu Kangyuan Pharmaceutical's exclusive product Ginkgo Diterpene Lactone Meglumine Injection applied for initial insurance. In 2023, at the end of China's public medical institutions, the sales of ginkgo diterpene lactone meglumine injection will be more than 900 million yuan.
Figure 1: Announcement of the latest acceptance of the protection of traditional Chinese medicine varieties
Source: NMPA official website
Ginkgo diterpene lactone meglumine injection is used for the meridians (mild to moderate cerebral infarction) in stroke during the convalescent period of phlegm stasis obstruction syndrome, the symptoms are hemiplegia, crooked mouth and tongue, slurred speech, limb numbness, etc., is the exclusive product of Jiangsu Kangyuan Pharmaceutical.
Figure 2: Sales of Ginkgo Diterpene Lactone Meglumine Injection (Unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Ginkgo biloba diterpene lactone meglumine injection is the TOP6 product in the terminal Chinese patent medicine cerebrovascular disease drug market in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), with sales of more than 980 million yuan in 2023 and a growth rate of 17.13%.
Table 1: The growth of more than 100 million products of Kangyuan Pharmaceutical in China's public medical institutions in 2023
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
According to data from Minenet, in 2023, Kangyuan Pharmaceutical will have 10 exclusive products with sales of more than 100 million yuan in the terminals of China's public medical institutions, among which Retoning Injection, Ginkgo Diterpene Lactone Meglumine Injection, Waist Bitong Capsule, Tianshu Capsule, Xingbei Cough Granules, and Tongsaimai Tablets have positive growth, and their strength should not be underestimated.
Table 2: Proprietary Chinese medicines submitted by Kangyuan Pharmaceutical Co., Ltd. for initial insurance applications since the beginning of this year
Source: NMPA official website
According to the statistics published on the official website of the NMPA, since the beginning of this year, Kangyuan Pharmaceutical has submitted three applications for the initial insurance of exclusive Chinese patent medicines, involving three categories: drugs for urological diseases, drugs for musculoskeletal system diseases, and drugs for cardiovascular and cerebrovascular diseases.
Source: Minenet database, NMPA official website
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated based on the average retail price of the product at the terminal. The statistics are as of July 2, if there are any omissions, please correct.